Tanja Obradovic
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Tanja Obradovic
Jul 6, 2024, 07:58 |
Drugs
Tanja Obradovic: Important lesson in development of the PDL-1 inhibitor just came in
Tanja Obradovic posted on LinkedIn: "Important lesson in the development of the PDL-1 inhibitor just…
Jul 6, 2024, 05:13 |
Insight
Tanja Obradovic: Choosing immunotherapy treatment for early resectable NSCLC
Tanja Obradovic shared on LinkedIn: "Choosing immunotherapy treatment options with PD(L)-1 inhibitors for early resectable non–small…
Jun 27, 2024, 02:53 |
Blog
Tanja Obradovic: Tempest Therapeutics just announced very good results from ongoing global clinical study with Amezalpat
Tanja Obradovic shared on LinkedIn: . “Are we to expect completely new mechanism of action…
Jun 24, 2024, 15:49 |
Insight
Tanja Obradovic: The landscape of targeting KRAS mutations just got busier
Tanja Obradovic shared on LinkedIn: . "The landscape of KRAS mutations…
Jun 13, 2024, 13:21 |
Drugs
Tanja Obradovic: How prevalent are policies that mandate step therapy for cancer drugs in the US?
Tanja Obradovic shared on LinkedIn: "How prevalent are health plan policies that mandate step therapy…
Jun 11, 2024, 06:28 |
Blog
Tanja Obradovic: Intriguing results reported at ASCO24
Tanja Obradovic shared a post on LinkedIn: ''What about intriguing results reported at ASCO24? One…
Jun 4, 2024, 13:13 |
Insight
Tanja Obradovic: NADINA trial making history at ASCO2024 plenary session
Tanja Obradovic shared on LinkedIn: . "NADINA trial making history today at ASCO2024 plenary session.…
Jun 3, 2024, 15:25 |
Societies
15 Posts From ASCO24 Day 3 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May…
Jun 3, 2024, 11:57 |
Societies
Tanja Obradovic: Very dynamic day at ASCO2024
Tanja Obradovic shared a post on LinkedIn: "Very dynamic ASCO2024 day as we learned quite…
Jun 1, 2024, 00:00 |
Blog
Tanja Obradovic: Gursel Aktan and Merck women's cancer team on just released positive OS data on KN 522
Tanja Obradovic shared a post on LinkedIn: "Congratulations to amazing leader in immunooncology drug development Gursel…
May 24, 2024, 01:22 |
Blog
Tanja Obradovic on Radiopharmaceuticals in oncology
Tanja Obradovic shared a post on LinkedIn: "Radiopharmaceuticals in oncology have been recently very active clinical…
May 22, 2024, 08:39 |
Blog
Tanja Obradovic: ASCO just published guidelines for germline genetic testing panels
Tanja Obradovic shared on LinkedIn: "Great service to public and oncology community as ASCO just published…
May 22, 2024, 03:53 |
Drugs
Tanja Obradovic: FDA just announced withdrawal of the approval for BridgeBio Pharma Truseltiq
Tanja Obradovic shared a post on LinkedIn: “FDA just announced withdrawal of the approval for BridgeBio…
May 22, 2024, 02:47 |
Insight
Visit ICON plc at ASCO24, booth 30119 to learn about One Search - ICON plc
Tanja Obradovic shared a post by ICON plc on LinkedIn, adding: “ASCO204 is almost to start.…
May 21, 2024, 00:56 |
Blog
Tanja Obradovic: Carisma Therapeutics just announced that first cancer patient with solid tumor received CAR-monocyte
Tanja Obradovic shared a post on LinkedIn: ''As of yesterday new cell therapy modality may be…
May 20, 2024, 02:15 |
Insight
Tanja Obradovic: Potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy
Tanja Obradovic shared on LinkedIn: "Questions around potential of TIGIT inhibitors to boost efficacy of PD(L)-1…
May 15, 2024, 09:38 |
Blog
Tanja Obradovic: Important PDUFA on June 12th is coming up
Tanja Obradovic shared a post on LinkedIn: "Important PDUFA on June 12th is coming up that…
May 15, 2024, 08:32 |
Blog
Tanja Obradovic: Private Biotech investment is on the steady rise reaching $3.1 billion in April
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: “Private Biotech investment is…
May 15, 2024, 04:12 |
Blog
Tanja Obradovic: News about effectiveness of PD-1 inhibitors in endometrial cancer continues to paint complex picture
Tanja Obradovic shared on LinkedIn: ''News about effectiveness of PD-1 inhibitors in endometrial cancer continues…
May 14, 2024, 11:07 |
Blog
Tanja Obradovic: At ASCO 2024 at the ICON plc booth we share thoughts on latest in cancer treatment innovation
Tanja Obradovic shared a post by ICON plc on LinkedIn, adding: ''This year we are certain…
May 12, 2024, 07:27 |
Drugs
Tanja Obradovic summarizes the latest news on immunotherapy with chemoradiation NSCLC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: “Based on what…
May 3, 2024, 23:43 |
Blog
Tanja Obradovic: All eyes are on ADCs coming from China's biotech innovation engine and CAR-T cell therapy
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc., shared a post on…
May 3, 2024, 04:53 |
Blog
Tanja Obradovic: Herceptin biosimilar Hercessi has just been approved by FDA
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc., shared a post on LinkedIn:…
May 2, 2024, 15:46 |
Insight
Tanja Obradovic: Battle with breast cancer is raging
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: "Battle with breast…
May 2, 2024, 15:25 |
Blog
Tanja Obradovic: Interesting updates will be coming on ASCO 2024
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: "ASCO 2024 is almost…
May 1, 2024, 10:55 |
Blog
Tanja Obradovic: The spotlight of FDA last week
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc., shared a post on LinkedIn:…
May 1, 2024, 09:57 |
Drugs
Tanja Obradovic: Dostarlimab chemotherapy in primary advanced or recurrent endometrial cancer
Tanja Obradovic, Vice President, Oncology Scientific Affairs at ICON, shared on LinkedIn: "Further inroads of…
Apr 28, 2024, 18:45 |
Blog
Tanja Obradovic: Absolutely great meeting and productive exchange around trends and needs in today's pharma world
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared a post by Why Summits…
Apr 20, 2024, 08:16 |
Blog
Tanja Obradovic: One exciting novel approach is just about to enter clinical development
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, shared a post on LinkedIn: "Cell…
Apr 17, 2024, 17:56 |
Blog
Tanja Obradovic: When during clinical development Medical Affairs Strategy should be started with the full force? Join for dialog and my presentation
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, shared a post on LinkedIn:…
Apr 17, 2024, 11:33 |
Drugs
Tanja Obradovic: What can we expect from antibody-drug conjugates (ADCs) in advanced ovarian cancer beyond Mirvetuximab?
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: “What…
Apr 13, 2024, 07:17 |
Blog
Tanja Obradovic: Exploring the Potential of B Cell Activation in Cancer Immunotherapy: Insights from AT-1965 Phase 1/2 Study
Tanja Obradovic, Vice President of Scientific Affairs at ICON plc., shared a post on LinkedIn: "In fighting cancer…
Apr 12, 2024, 17:18 |
Drugs
Tanja Obradovic: Interesting statistics on the nature of licensing deals in pharmaceutics during last year
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: “Interesting…
Apr 12, 2024, 16:43 |
Drugs
Tanja Obradovic: Exciting new vaccine is about to start Phase III in advanced NSCLC patients that progressed following immunotherapy
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: “Exciting…
Apr 12, 2024, 05:16 |
Drugs
Tanja Obradovic: Era of antibody drug conjugates just got even more exciting with the first tumor-agnostic approval for ADC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, recently shared on LinkedIn: "Era…
Mar 10, 2024, 20:14 |
Blog
Tanja Obradovic: Access24 meeting was outstanding gathering of experts across product value aspects
Tanja Obradovic, Vice President, Oncology Scientific Affairs at ICON plc, Medical Affairs, shared a post on…
Feb 17, 2024, 16:27 |
Drugs
Tanja Obradovic: BioXcel Therapeutics received Fast Track designation by the FDA for BXCL701
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: "Biotech companies…
Jan 31, 2024, 23:59 |
Insight
Tanja Obradovic: Outstanding work from UK
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, shared a post by…
Jan 24, 2024, 08:04 |
Blog
Tanja Obradovic: Clinical development includes the need to have critical focus on inclusion and diversity
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, shared a post by…
Dec 21, 2023, 10:06 |
Blog
Tanja Obradovic: Asia Biotech companies are driving major advances in oncology this year
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON plc, posted on LinkedIn: "Asia…
All:
40
Posts:
1 - 100
The largest philanthropic partnership in The V Foundation’s history - Dolphins Cancer Challenge
Glecirasib: A Promising Novel KRAS G12C Inhibitor in Clinical Development
How the Médecins Sans Frontières Journal Inspired a Lifetime of Humanitarian Service: Paul Spiegel
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube